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Abstract
Background: Human clear cell renal cell carcinoma (CRCC) remains resistant to therapies.
Recent advances in Hypoxia Inducible Factors (HIF) molecular network led to targeted therapies,
but unfortunately with only limited clinical significance. Elucidating the molecular processes
involved in kidney tumorigenesis and resistance is central to the development of improved
therapies, not only for kidney cancer but for many, if not all, cancer types. The oncogenic PI3K/Akt,
NF-kB and MAPK pathways are critical for tumorigenesis. The sonic hedgehog (SHH) signaling
pathway is crucial to normal development.
Results: By quantitative RT-PCR and immunoblot, we report that the SHH signaling pathway is
constitutively reactivated in tumors independently of the von Hippel-Lindau (VHL) tumor
suppressor gene expression which is inactivated in the majority of CRCC. The inhibition of the
SHH signaling pathway by the specific inhibitor cyclopamine abolished CRCC cell growth as
assessed by cell counting, BrdU incorporation studies, fluorescence-activated cell sorting and β-
galactosidase staining. Importantly, inhibition of the SHH pathway induced tumor regression in
nude mice through inhibition of cell proliferation and neo-vascularization, and induction of
apoptosis but not senescence assessed by in vivo studies, immunoblot and immunohistochemistry.
Gli1, cyclin D1, Pax2, Lim1, VEGF, and TGF-β were exclusively expressed in tumors and were
shown to be regulated by SHH, as evidenced by immunoblot after SHH inhibition. Using specific
inhibitors and immunoblot, the activation of the oncogenic PI3K/Akt, NF-kB and MAPK pathways
was decreased by SHH inhibition.
Conclusions: These findings support targeting SHH for the treatment of CRCC and pave the way
for innovative and additional investigations in a broad range of cancers.
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Background
Renal cell carcinoma (RCC) is the most lethal urologic
tumor and the sixth leading cause of cancer deaths in
Western countries. Each year, around 200,000 patients are
diagnozed with this malignancy resulting in approxi-
mately 100,000 deaths, and its incidence is increasing
steadily [1,2]. RCC is represented by 80% by clear cell
RCC (CRCC), originating from the renal proximal tubule.
RCC is resistant to radio-, hormono-, and chemotherapy,
and immunotherapy is effective in only 15% of selected
patients [3]. The recent development of anti-angiogenic
strategies based on small molecule tyrosine kinase recep-
tor inhibitors lead to the approval of sunitinib or soraf-
enib as first-line therapy for RCC [2-5].
So far the best known oncogenic signal in human CRCC
is constituted by the von Hippel-Lindau (VHL) tumor
suppressor gene and hypoxia-induced factors (HIFs).
Inherited and sporadic forms of CRCC are associated with
inactivation of the VHL gene [6,7]. In hypoxic conditions,
or when the VHL gene is defectuous as it is the case in 60%
of CRCC, HIFs-α are stabilized allowing the expression of
a large panel of target genes involved in growth, motility,
metabolism and angiogenesis such as vascular endothe-
lium growth factor (VEGF), tumor growth factors (TGFs),
parathyroid hormone-related protein (PTHrP), glucose
transporters and transferrin [1,7], all shown to contribute
to CRCC tumorigenesis.
Additional oncogenic events are required for CRCC for-
mation, and such concept has been clearly evidenced by
molecular and genetic approaches [8]. We and others
have shown that the proliferative and survival signaling
pathways such as the PI3K/Akt, NF-κB and MAPK path-
ways are constitutively activated and turned towards
tumor growth in human CRCC [9-11]. The idea that
tumors hijack for their own growth signaling pathways
involved in normal development is emerging. In human
CRCC, this is the case for at least the Pax2 and 8 transcrip-
tion factors and Notch signalling [12,13].
The hedgehog pathway is critical for embryonic and post-
natal organ and tissue development, including the kidney.
The sonic hedgehog (SHH) signaling pathway has also
been shown to be dysregulated in pancreatic and colorec-
tal cancers and melanomas [14], resulting in the induc-
tion of the expression of numerous target genes that
regulate cell proliferation, cell differentiation, cell death,
extracellular matrix interactions, and angiogenesis [15].
The SHH pathway interacts with various oncogenic path-
ways including the PI3K/Akt, the NF-κB, the MAPK path-
ways and the Notch pathway, another important
developmental pathway. Interestingly, these pathways
have been shown by us and others to be critical for human
CRCC tumorigenesis [9-13]. To date and to our knowl-
edge no studies have been conducted to assess the impor-
tance of the SHH pathway in human CRCC tumorigenesis
and that was the purpose of the present study.
We found that the SHH signalling pathway is reactivated
in human CRCC and that it converges to various onco-
genic pathways to orchestrate tumor growth. In addition,
we identified various Gli1 targets some never previously
described such as Smo and the transcription factor Lim1
that is also necessary for normal kidney development.
Results
SHH signaling pathway components are constitutively 
expressed in human CRCC cells independently of VHL 
expression
The SHH ligand expression was detected in untransfected
786-0 cells (wt) and in 786-0 cell either untransfected or
transfected with the various VHL constructs, as well as in
a panel of human CRCC cell lines expressing or not VHL
(Figure 1A).
All the components of the SHH signaling pathway, i.e
SHH ligand, Ptch1, Smo and the downstream transcrip-
tion factors Glis were expressed in all cells (Figure 1B). In
all cases, except A498 cells, Smo was the highest expressed
component. There was no difference in expression
depending on the VHL status (Figure 1B).
Thus, the SHH signaling pathway is constitutively
expressed and activated in tumor cells and independently
of VHL expression.
SHH signaling pathway components are constitutively 
reexpressed in human CRCC tumors
The SHH ligand was detected in all tumor samples as well
as in normal corresponding tissues for all stages except for
patient 8 (T8) where SHH was undetectable in normal tis-
sue (N8) (Figure 2A).
The Ptch1 receptor ratio was very variable from one N/T
sample pair to another being either less expressed in nor-
mal tissue, equally expressed in tumors and normal tis-
sues or higher in normal tissue (Figure 2B). Interestingly,
the expression of the Smo receptor was considerably
higher (300 to 1,000 fold increase) in tumors compared
to normal corresponding tissues for all N/T pairs tested
(Figure 2C). The expression of the Gli1 transcription fac-
tor was also increase about two- to five- fold in tumors
compared to normal corresponding tissues (Figure 2D).
Taken together these results show that the SHH signaling
pathway is active in tumors compared to normals.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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All the SHH signaling pathway components are expressed in human CRCC cells independently of VHL expression Figure 1
All the SHH signaling pathway components are expressed in human CRCC cells independently of VHL expres-
sion. (A) Western blot analysis of the SHH ligand in human CRCC cell lysates incubated with antibodies against human SHH 
ligand and corresponding β-actin. The expression of the ligand was assessed in 786-0 cells either untransfected (786-0 wt) or 
transfected with the vector alone (786-0 V), the full-length human VHL cDNA (786-0 VHL) or truncated inactive VHL cDNA 
sequence (786-0 ΔVHL), as well as in a panel of human CRCC cell lines either deficient in VHL expression (Deficient in VHL) 
or expressing VHL (Expressing VHL). The gels shown are representative for at least 3 independent experiments. (B) Quantita-
tive gene expression of SHH ligand, of Ptch1 and Smo receptors, and of the Glis transcription factors (Gli1, Gli2 and Gli3) in 
the same panel of cells depicted in (A). Results are shown as mean ± SEM, n = 4.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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SHH signaling pathway inhibition decreases human CRCC 
cell proliferation independently of VHL expression
Cyclopamine at 20 μM decreased cell proliferation by up
to 80% after 5 days of treatment (Figure 3A). The effect of
the inhibitor was concentration-dependent with a maxi-
mal effect of 90% inhibition of cell proliferation at 40 μM
at day 5 (Figure 3B). For the rest of the experiments we
choose tu use cyclopamine at 20 μM, a concentration near
the IC50 on cell growth.
The efficacy of the inhibitory effect of cyclopamine was
not dependent on the VHL status and was identical also in
our panel of human CRCC cell lines (Figure 3C).
The effect of cyclopamine on cell growth was due in a
large part to inhibition of cell proliferation as assessed by
BrdU incorporation studies in 786-0 wt cells, in 786-0 V,
786-0 VHL and 786-0 ΔVHL (Figure 3D), with a maximal
inhibitory effect of 80-90%. Thus, this effect was not
dependent on VHL status.
Since the possibility exists that cyclopamine may affect
other pathways we used an alternate approach to inhibit
the SHH pathway using siRNA targeting key components
of this pathway, i.e the Smo receptor and the Gli1 tran-
scription factor. In transient transfection assays, both siR-
NAs decreased cell growth in a time (Additional file 1A)
and concentration-dependent (Additional file 1B) man-
ner by up to 80% at day 4. Such effects were observed in
our panel of human CRCC cell lines (Additional file 1C)
and again, this effect was mainly due to inhibition of cell
proliferation, as assesed by BrdU incorporation (Addi-
tional file 1D).
Taken together, these data show that the inhibition of the
SHH pathway decreases tumor cell growth essentially by
affecting cell proliferation.
SHH signaling pathway inhibition increases human CRCC 
cell apoptosis but not senescence
Because the inhibition of cell proliferation by
cyclopamine was not complete we also assessed whether
the inhibitor was inducing apoptosis in human CRCC
cells. Cyclopamine was inducing cell apoptosis in a time-
dependent manner reaching a maximal induction of cell
apoptosis of 12% (Figure 4A and 4B). As for cell prolifer-
ation assays, similar effects were observed in cells tran-
siently transfected with siRNAs targeting Smo and Gli1
(Additional file 2). No effects of cyclopamine treatment
were observed on tumor cell senescence (Additional file
3).
Thus, the growth inhibitory effects of SHH pathway inhi-
bition is obtained mainly through a decrease of cell pro-
liferation and in a lesser degree through induction of cell
apoptosis in human CRCC.
All the SHH signaling pathway components are expressed in human CRCC tumors Figure 2
All the SHH signaling pathway components are expressed in human CRCC tumors. (A) Western blot analysis of 
the SHH ligand in 9 human tumors (T1 ...) and normal corresponding tissues (N1 ...) lysates incubated with antibodies against 
human SHH ligand and corresponding β-actin. The gels shown are representative for at least 3 independent experiments. (B) 
Quantitative gene expression of Ptch1 and Smo receptors, and of the Gli1 transcription factor in the same normal/tumoral tis-
sue pairs shown in (A). Results are representative of 4 independent experiments.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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Transfection with Smo and Gli1 expression vectors 
alleviates the growth inhibitory effects of cyclopamine in 
human CRCC cells
To argument further the adequate targeting of
cyclopamine against the SHH signaling pathway, we tran-
siently transfected 786-0 cells for 0 to 5 days with Smo
and Gli1 expression vectors (pCMV6-XL5-Smo and
pCMV6-XL5-Gli1, respectively) or vector alone (pCMV6-
XL5). We then assessed and compared the effects of
cyclopamine on cell growth in cells transfected with these
vectors and in untransfected cells. The overexpression of
Smo and Gli1 was maximal 2 to 3 days post-transfection
as assessed by western blot and quantitative RT-PCR (data
not shown). The transfection with vector alone did not
affect tumor cell proliferation at any time (Additional file
4). Interestingly, the transfection with Smo or Gli1 vector
significantly increased cell proliferation 2 to 3 days post-
transfection by up to 20-25% (Additional file 4). As
expected from results presented on Figure 3, cyclopamine
alone decreased cell proliferation by up to 80% at day 5
(Additional file 4). While the transfection with vector
alone did not affect the inhibitory effect of cyclopamine
on cell proliferation, the transfection with either Smo or
Gli1 vectors alleviated significantly the growth inhibitory
effect of cyclopamine at all times tested (Additional file
4).
These results show that overexpression of key compo-
nents of the SHH signaling pathway not only has growth
stimulatory effects on tumor cells but also alleviates the
growth inhibitory effect of cyclopamine. These data
clearly argument that the effect of cyclopamine is the con-
sequence of SHH signaling pathway inhibition.
Specificity of cyclopamine towards the SHH signaling 
pathway in human CRCC cells
To check further the specificity of the inhibitor towards
the SHH signaling pathway, we measured the expression
of all the molecular components of the pathway by west-
ern blot or quantitative analysis of mRNAs expression in
786-0 cells. The expression of the SHH ligand was surpris-
ingly, but interestingly, decreased as a function of time by
cyclopamine, suggesting that the SHH ligand may itself be
a target of the SHH pathway (Figure 5A).
Cyclopamine also decreased the expression of Ptch1 and,
interestingly, of Smo receptors (Figure 5B), suggesting fur-
ther that Smo may also be a target of the SHH pathway.
Cyclopamine treatment decreased the expression of the
transcription factors Gli1 and Gli2 (Figure 5B). The
expression of Gli3, the endogenous repressor of the SHH
pathway, was increased by cyclopamine treatment (Figure
5B). The effect of the inhibitor on gene expression was
observed with different velocities from one component to
another.
Overall, these results argue further for the specificity of the
Smo inhibitor towards the SHH signaling pathway, and
put in evidence two additional targets of the pathway,
Ptch1 and Smo receptors.
Cyclopamine injection induces tumor regression in nude 
mice bearing human CRCC tumors
We next analyzed the effect of cyclopamine in vivo in the
tumor xenografted nude mice model. In the first protocol
(injections every other day), tumor growth was com-
pletely abolished by cyclopamine treatment (Figure 6A
and Additional file 5A). The expression of Gli1 was
decreased by 80% in tumors harvested from cyclopamine-
treated mice compared to tumors from control mice
showing adequate targeting of the drug (Figure 6A, top
gels).
The anti-tumor effect obtained following the first protocol
prompted us to assess in a second protocol whether we
could observe tumor regression with cyclopamine by
increasing the overall dose of the SHH inhibitor in tumor-
bearing mice. In the second protocol (daily injections),
cyclopamine induced more than 50% tumor regression
(Figure 6B and Additional file 5B). The expression of Gli1
was also substantially decreased in tumors harvested from
cyclopamine-treated mice by more than 80% (data not
shown).
The inhibition of the SHH signaling pathway decreases human CRCC cell proliferation Figure 3 (see previous page)
The inhibition of the SHH signaling pathway decreases human CRCC cell proliferation. (A) Human 786-0 cells 
were treated in control (Ctl) or with cyclopamine (Cyclopamine, 20 μM) and cells were counted each day. Results are shown 
as mean ± SEM, n = 6; *, P < 0.05; **, P < 0.01 from Ctl. (B) Human 786-0 cells were treated for 5 days in control (Ctl) or with 
cyclopamine (Cyclopamine) and adherent cells were counted. Results are shown as mean ± SEM, n = 6; **, P < 0.01 from 0 
(without cyclopamine). (C) Our panel of human CRCC cells either deficient or expressing VHL were treated treated for 5 days 
in control (Ctl) or with cyclopamine (Cyclopamine, 20 μM) and adherent cells were counted. Results are shown as mean ± 
SEM, n = 6; **, P < 0.01 from Ctl (without cyclopamine) that was set to 100%. (D) Human 786-0 wt, 786-0 V, 786-0 VHL and 
786-0 πVHL cells were analyzed for BrdU incorporation after treatment in control (Ctl) or with cyclopamine (Cyclopamine, 20 
μM), for the indicated periods of time. Results are shown as mean ± SEM, n = 6; *, P < 0.05; **, P < 0.01 from corresponding 
Ctl.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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The inhibition of the SHH signaling pathway induces human CRCC cells apoptosis Figure 4
The inhibition of the SHH signaling pathway induces human CRCC cells apoptosis. FACS analysis of 786-0 treated 
in control (Ctl) or with cyclopamine (Cyclopamine) at 20 μM. (A) Exemples of FACS analysis (day 4). No evidence of necrosis 
was observed in any cases. (B) Quantitative analysis of apoptotic cells as a function of the time of treatments. Results are 
shown as mean ± SEM, n = 6 *, P < 0.05 and **, P < 0.01 from Ctl apoptosis. Bars, 5 μm.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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Cyclopamine treatment decreases the expression of the SHH ligand, Smo receptor, Gli1 factors, and increases the expression  of the Ptch1 Figure 5
Cyclopamine treatment decreases the expression of the SHH ligand, Smo receptor, Gli1 factors, and increases 
the expression of the Ptch1. (A) Human 786-0 CRCC cells were seeded and treated for the indicated periods of time in 
control (Ctl) or with cyclopamine (Cyclopamine, 20 μM). Shown are western blot analysis of the SHH ligand in cell lysates 
from cells treated in each condition and incubated with antibodies against human SHH ligand and corresponding β-actin. The 
gels shown are representative for at least 3 independent experiments. (B) Human 786-0 CRCC cells were seeded and treated 
for the indicated periods of time in control (Ctl) or with cyclopamine (Cyclopamine, 20 μM). Quantitative gene expression of 
Ptch1, Smo receptors, Gli1, Gli2 and Gli3. Results are shown as mean ± SEM, n = 6 *, P < 0.05 from cells treated in Ctl at the 
same time point.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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Figure 6 (see legend on next page)Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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To assess wether the inhibitory effect on tumor growth of
cyplopamine was long-lasting, in the mice treated using
the second protocol, the control and cyclopamine treat-
ments were stopped at day 10 and tumors were left grow-
ing for an additional 14 days period. In mice treated with
cyclopamine, tumors did not grow further while in con-
trol mice the tumors' volume doubled (Figure 6B).
We used tumors harvested from mice treated according to
the first protocol to assess the effect of cyclopamine on
cell proliferation, death and on angiogenesis. Indeed for
the second protocol mice were left untreated for several
days and this not allow us to determine the effect of the
drug on such tumor parameters. The proliferative index
was significantly decreased by about 25% in mice treated
with cyclopamine compared to mice treated in control
(Figure 6C). Curiously, cyclopamine treatment did not
influence tumor cell apoptosis (Additional file 5C). How-
ever such an effect may be due to the time between the last
injection of cyclopamine and analysis, i.e 3 days. Very
interestingly, tumor neovascularization was decreased sig-
nificantly by cyclopamine treatment (Figure 6D).
These results suggest that the SHH signaling pathway
plays a critical role in tumor growth in vivo mainly by
affecting cell proliferation and vessel generations in
human CRCC tumors.
The SHH signaling pathway plays orchestral roles in 
oncogenic pathways stimulation in human CRCC
We next investigated the connection between the SHH sig-
naling and known oncogenic pathways, i.e the PI3K/Akt
(and GSK3), NF-κB and MAPK pathways. For that, we
used cyclopamine or cells transiently transfected with
siSmo or siGli1 targeting siRNAs alone or in combination
with inhibitors of oncogenic pathways in 786-0 cells. The
inhibitory effect of cyclopamine on cell growth was not
additive with the effects of inhibitors of each pathway,
suggesting strongly that the SHH signaling is linked to the
activity of GSK-3 and to the oncogenic PI3K/Akt, NF-κB
and MAPK pathways (Additional file 6). The effects of the
GSK-3 and NF-κB inhibitors alone was observable only at
day 1 and day 2 of treatments, while the effect of the PI3K/
Akt and MAPK inhibitors lasted during the 5 days of the
experiments (Additional file 6), suggesting a sequential
activation of these pathways. Similar results were
obtained after Smo or Gli1 silencing (Additional file 7).
We next evaluated the effect of cyclopamine and of Smo
and Gli1 silencing through transient transfection on GSK-
3 activation and of all of the above-mentioned signaling
pathways by western blot in 786-0 cells. The non-phos-
phorylated states of GSK-3, Akt, NF-κB and Erk1/2 remain
unchanged after cyclopamine treatments (Figure 7A).
However, cyclopamine treatments induced a decrease in
the phosphorylation state of Akt, NF-κB and Erk1/2, and
an increase in the phosphorylated state of GSK-3 (Figure
7A), thus inhibiting their biological activities. Again, sim-
ilar results were obtained after Smo or Gli1 silencing
(Additional file 8).
These results argue for an orchestral role for SHH signal-
ing in the constitutive activation of oncogenic pathways in
this pathology.
We tested a panel of genes known for some of them to be
Gli's targets in other cell lines or tissue types and shown to
be important in human CRCC tumorigenesis, i.e Gli1
itself, cyclin D1, Pax2, Lim1, VEGF and TGF-β. By treating
786-0 cells with cyclopamine for 1 or 2 days, we showed
that all of the tested targets were under the transcriptional
activity of the SHH signaling pathways except cyclin D1,
and that Pax2 expression was only inhibited at day 1 of
cyclopamine treatment (Figure 7B).
In all patients tested, Gli1, cyclin D1, Pax2 and Lim1 were
expressed exclusively in tumors at all stages (Figure 7C).
The expression of VEGF and TGF-β were not assessed in
these patients because these factors are known to be
expressed in tumors and in a lesser degree in normal
counterparts in human CRCC [2].
Inhibition of the SHH signaling pathway induces tumor regression in nude mice Figure 6 (see previous page)
Inhibition of the SHH signaling pathway induces tumor regression in nude mice. (A) Tumor growth in mice treated 
according to the first experimental protocol. Results are shown as mean ± SEM, n = 7 for both groups; **, P < 0.01 
cyclopamine-treated mice vs Ctl-treated mice. Immunoblotting experiments to measure expression of Gli1 in tumors lysates. 
The gels shown are representative for at least 3 independent experiments. Photographs show the implanted tumors in repre-
sentative mice at day 1 of drug injection, at day 19 in Ctl-treated group or cyclopamine-treated group. (B) Tumor growth in 
mice treated according to the second protocol. Results are shown as mean ± SEM, n = 7 for both groups; **, P < 0.01 
cyclopamine-treated mice vs Ctl-treated mice. (C) Left, tumor sections of control- (Ctl) or cyclopamine (Cyclopamine)-treated 
mice immunostained with an antibody against Ki67 (magnification ×400). Right, proliferative index. Results are shown as mean 
± SEM, n = 7. **, P < 0.01 from Ctl-treated mice. (D) Left, tumor sections of control- (Ctl) or cyclopamine (Cyclopamine)-
treated mice immunostained for CD31 (magnification ×400). Right, quantification of neovascularization. Results are shown as 
mean ± SEM, n = 7. *, P < 0.05 from Ctl-treated mice.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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In conclusion, various Gli target genes have found to be
specifically expressed in tumors, clearly argumenting the
pivotal role played by the SHH signaling pathway in
human CRCC.
Discussion
The SHH signaling pathway plays crucial roles in meta-
zoan embryo patterning [16]. During nephrogenesis, the
biological effects of the SHH signaling pathway concern
cell differentiation, migration and growth as well as ang-
iogenesis [17]. Inherited or acquired modifications or
abberations in components of the SHH cascade result in
various phenotypes such as congenital anomalies (Pal-
lister-Hall syndrome and holoprosencephaly) and various
cancers including basal cell carcinoma and gastrointesti-
nal cancers [18,19].
We show that this pathway is constitutively expressed and
activated in human CRCC both in vitro and in vivo in
freshy harvested tumors and in tumors grown in nude
mice. The SHH ligand was expressed in cells and tumors
but there was no consensus as for a preferential expression
in tumors vs. normal corresponding tissues. This may be
explained in part by diffusion of the SHH ligand secreted
by the tumor to the adjacent normal tissues. Alternatively,
some cells, such as resident stem cells, may expressed SHH
ligand as suggested by other studies, arguing for a role for
SHH pathway in the maintenance of the stem cell com-
The SHH signaling pathway plays a pivotal and orchestral role in the constitutive activation of oncogenic pathways in human  CRCC Figure 7
The SHH signaling pathway plays a pivotal and orchestral role in the constitutive activation of oncogenic path-
ways in human CRCC. (A) Western blots analysis of human CRCC 786-0 cell lysates treated for 2 days in control (Ctl) or 
with cyclopamine (Cy) at 20 μM and incubated with the antibodies against non-phosphorylated GSK-3 (GSK-3), phospho-GSK-
3 (P-GSK3), non-phosphorylated Akt (Akt), phospho-Akt (P-Akt), non-phosphorylated NF-κB (NF-κB), phospho-NF-κB (P-
NF-κB), non-phosphorylated Erk1/2 (Erk1/2), phospho-Erk1/2 (P-Erk1/2) and corresponding β-actin. The gels shown are rep-
resentative for at least 3 independent experiments. (B) Western blots analysis of human CRCC 786-0 cells lysates treated for 
2 days in control (Ctl) or with cyclopamine (Cy) at 20 μM and incubated with the antibodies against Gli1, cyclin D1, Pax2, Lim1, 
VEGF, TGF-β1 and corresponding β-actin. The gels shown are representative for at least 3 independent experiments. (C) 
Western blot analysis in 9 human tumors (T1 ...) and normal corresponding tissues (N1 ...) lysates incubated with antibodies 
against Gli1, cyclin D1, Pax2, Lim1, and corresponding β-actin. The gels shown are representative for at least 3 independent 
experiments.Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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partment [20,21]. Our results clearly show that the SHH
signaling pathway is active in tumors but not in normal
kidney tissues, as evidenced by the elevated expression of
Smo and Gli transcription factors in tumors vs. corre-
sponding normal tissues. As no data has been reported
about the involvement of the SHH signaling pathway in
human CRCC, it remains unknown whether there are acti-
vating mutations of this pathway. Our data suggest that
the erroneous activation of this pathway in human CRCC
may results from the expression of the Ptch1 receptor and
the signaling components Smo and Gli.
The SHH ligand was present in all cell lines tested whether
or not they are expressing VHL and the level of expression
of SHH, Smo, Gli1, Gli2 and Gli3 were identical in 786-0
cells untransfected or VHL constructs-transfected cells.
Although some studies have reported crosstalk between
SHH and HIF pathways in other systems [22], our data
suggest that the activation state of the SHH signaling is
not associated with the VHL/HIF system in human CRCC.
Our results show that the SHH signaling pathway pro-
motes tumor cell growth in human CRCC, regardless of
the VHL status. The specificity of the Smo inhibitor
cyclopamine against the SHH signaling pathway was
clearly demonstrated herein by showing that overexpres-
sion of Smo and Gli1 alleviates the growth inhibitory
effect of cyclopamine and by the negative effect of the
Smo inhibitor on the expression not only of the SHH lig-
and but also of Gli1 and Gli2. Surprisingly, the expression
of Ptch1 was increased by cyclopamine treatment, sug-
gesting that Ptch1 expression might be repressed by the
transcriptional activity of the SHH signaling pathway in
human CRCC; this contrasts with what has been observed
in other systems [15]. The expression of Smo was also
decreased by the Smo inhibitor but at later time points
suggesting that Smo may be transcriptionnally regulated
by Gli transcription factors. In human CRCC, we show,
using various experimental approaches, i.e cyclopamine,
Smo and Gli1 targeting siRNAs and Smo and Gli1 overex-
pression, that the SHH signaling pathway stimulates
essentially cell proliferation and in a lesser degree inhibits
cell death, and no effects were observed on tumor cell
senescence.
Interestingly, SHH signaling inhibition induced substan-
tial tumor regression in nude mice, and the inhibitory
effect on tumor growth was long-lasting after treatment
arrest. Such spectacular effects of SHH signaling inhibi-
tion on tumor growth were also observed in other cancers
such as human cholangiocarcinoma and melanomas
[23]. Herein, we also showed that the treatment of human
CRCC tumor-bearing nude mice with cyclopamine
decreases tumor vascularization, indicating that the SHH
pathway stimulates neoangiogenesis in human CRCC.
Moreover, we showed that the expression of the ang-
iogenic and growth factors VEGF and TGF-β are under the
transcriptional control of the SHH signaling pathway, and
thus that they are probably part of the targets mediating
this effect in human CRCC. However, reports of the prog-
nostic value of vascularization in human CRCC have
shown either no effect on patient survival, better survival
or worse prognosis [24-26]; these discrepancies may be
the consequence of vessel size and/or the co-existence of
different vessels depending on the expressed markers
CD31 and CD34 [27].
The PI3K/Akt, NF-κB, MAPK, Jun kinase, Notch and SHH
signaling pathways have been shown to be the main sign-
aling events involved in nephrogenesis [28,29]. Interest-
ingly, these pathways are activated constitutively in
human CRCC. Our results demonstrate clear interactions
between the PI3K/Akt, NF-κB, MAPK, and SHH signaling
pathways in human CRCC. As GSK-3 has been shown to
inhibit Glis functions [30], it was surprising to observe
that GSK-3 phosphorylation was increased in response to
SHH inhibition using cyclopamine and Smo and Gli1 tar-
geting siRNAs. However, the Akt-independent phosphor-
ylation of GSK-3 may have opposite effect on GSK-3
activity. Finally, NF-κB has been shown to contribute to
SHH signaling activation through SHH ligand induction
in pancreatic cells [31]. The inhibitory effect of
cyclopamine and of Smo and Gli1 silencing on NF-κB
activation observed here thus suggests that the SHH sign-
aling stimulates NF-κB, which itself stimulates SHH sign-
aling. Therefore, our results provide evidence for a pivotal
and orchestral role for SHH signaling pathway in the con-
stitutive activation of oncogenic pathways leading to sus-
tained tumor growth.
As stated above, various Gli targets have been evidenced
[15]. We identified various genes being under the tran-
scriptional activity of Gli. There are some reports in the lit-
erature describing the involvement of cyclin D1 and Pax2
in human CRCC tumorigenesis [32,33] and for Pax2 in
responses to therapies, but not for the SHH ligand, Gli1
and Lim1. Interestingly, the SHH ligand itself was shown
to be a transcriptional target of the SHH signaling. Thus,
the system boosts itself by also increasing the expression
of the ligand.
Conclusions
Until the recent development of targeted therapies with
multi-tyrosine kinase receptors inhibitors such as
sunitinib and sorafenib, and although their effects are not
long-lasting due to therapy-induced resistance, there was
no efficient treatment for advanced human CRCC. Our
results indicate that inhibition of SHH signaling might
represent a new and complementary therapeutic
approach against human CRCC. As SHH signaling path-Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
Page 13 of 16
(page number not for citation purposes)
way has emerged as a crucial pathway in the pathogenesis
of various tumor types, SHH inhibitors are currently being
evaluated as potential anticancer drugs. Here, we showed
that cyclopamine was safe and well tolerated by the mice,
providing the proof of concept for the use of this family of
drugs in vivo.
Overall, we showed that the SHH pathway is specifically
reactivated in human CRCC and that targeting this path-
way might be particularly efficient against this disease, not
only through inhibition of tumor growth but also by
impeding tumor vascularization. Because CRCC is resist-
ant to therapies, describing and understanding all the
molecular mechanisms leading to carcinogenesis is criti-
cal to develop treatment for this cancer type. Thus, our
study identifies the SHH pathway as an important signal-
ing pathway implicated in kidney tumorigenesis.
Methods
Cell culture and reagents
Human CRCC cell lines either deficient in VHL (786-0,
UOK-126, A498) or expressing VHL (ACHN, Caki-2) as
described [9]. Clones of 786-0 cells transfected either with
human VHL gene (786-0 VHL), inactive troncated human
VHL gene (786-0 ΔVHL), or the vector alone only pCR3-
Uni (786-0 V) were also used.
Human tumor biopsies
The tumor and normal corresponding tissue of 9 patients
were obtained in collaboration with the Department of
Urology (Pr. D. Jaqmin and Pr. H. Lang) of the "Nouvel
Hôpital Civil" (NHC), Strasbourg, France. Informed con-
sent was obtained from all patients. The tumors were
staged according to the tumor node metastasis (TNM)
classification [34]: 2 pT1aNx, 1 pT1bNx,, 1 pT2N0, 1
pT2Nx,, 1 pT3aNx, 2 pT3bN0 and 1 pT3bN1 (T1 to T9).
Immediately after surgical resection, tissues were fresh fro-
zen and kept in liquid nitrogen until RNA and protein
expression analysis.
Western Blot Analysis
Protein extractions and membrane preparations were per-
formed as described [35]. Membranes were incubated
overnight at 4°C with the appropriate dilution of the fol-
lowing primary antibodies: anti-Akt antibody (1:250; Mil-
lipore), anti-phospho-Akt antibody (1:150; Ozyme, Cell
signaling local distributor, Saint-Quentin-en-Yvelines,
France), anti-GSK3α/β  antibody (1:1000; Millipore 05-
903), anti-phospho-GSK3α/β (Ser21/9) antibody (1:250;
Ozyme), anti-NF-κB (1:2000; Millipore AB1604), anti-
phospho-NF-κB (S468) (1:250; Ozyme); anti-Erk1/
(1:1000; Ozyme), anti-phospho-Erk1/2 (1:1000; Milli-
pore 05-481), anti-SHH (1:500; Ozyme), anti-cyclinD1
(1:750; Ozyme), anti-Gli1 (1:2000; Millipore AB3444),
anti-Pax2 (1:1000; Ozyme), anti-Lim1 (1:3000; Millipore
AB3200), anti-VEGF (1:250; Millipore MAB3734) and
anti-TGFβ1 (1:200; Ozyme). For visualization of protein
gel loading, an anti β-actin antibody was used (1:5000;
Sigma-aldrich, St Quentin Fallavier, France). The appro-
priate horseradish peroxidase-conjugated secondary was
used. Immunoreactivity was visualized as detailed [35].
Real-time quantitative RT-PCR analysis
Total RNAs were extracted from CRCC cells and tissues
using the Trizol method according to the manufacturer's
protocol (Invitrogen). Five μg of total RNA were reverse
transcribed in a reaction buffer (Invitrogen) and non-spe-
cific primer p(dT)15 (Roche Diagnostics, Meylan, France),
at 37°C for 1 h. cDNAs specific for each Ptch1, Smo, Gli1,
Gli2, Gli3 and SHH mRNAs were amplified using the
"LightCycler-FastStart DNA Master SYBR (syber) Green"
kit (Roche Diagnostics). Sense and antisens primers used
are depicted in Additional file 9. Each sample was ana-
lyzed 3 times and quantified with the analysis software for
LightCycler (Roche Diagnostics).
Cell density
CRCC cell proliferation was assessed by counting adher-
ent cells, as described [35]. RCC cells were seeded in 24-
well plates (20,000 cells/ml), grown for 24 h, and then
treated for 1-5 days with various concentrations of
cyclopamine (LC Laboratories, Woburn, USA), SB216763
(GSK3 inhibitor, Sigma-Aldrich), LY294002 (PI3K inhib-
itor, Sigma-Aldrich), BAY 11-7085 (NF-κB inhibitor, Cal-
biochem, Fontenay-sous-Bois, France), or U0126 (MAPK
inhibitor, Calbiochem), alone or in combination, as indi-
cated in the appropriate Figures or Figure legends, or the
diluent only (DMSO). In some experiments, we also used
Smo and Gli1 targeting siRNAs and Smo and Gli1 express-
ing vector and assessed cell density, either alone or in
combination with cyclopamine or the above-mentioned
oncogenic pathways inhibitors, as indicated in the appro-
priate Figures or Figure legends.
Bromodeoxyuridine (BrdU) incorporation
CRCC cells were seeded in 96-well plate (20,000 cells/
ml), grown for 24 h and FBS was replaced by 0,1% of BSA
during an additional 24 h to render cells quiescent. Cells
were treated for 1-5 days with 20 μM cyclopamine or the
corresponding volume of DMSO. In some experiments,
we also used Smo and Gli1targeting siRNAs and per-
formed BrdU incorporation studies, as indicated in the
appropriate Figures or Figure legends. Test was then real-
ized according to the protocol of the manufacturer (Calbi-
ochem®, Merck KGaA, Darmstadt, Germany).
Fluorescence-Activated Cell Sorting Analysis
CRCC cells were seeded in 6-well plates (20000 cells/ml)
and treated with 20 μM cyclopamine or DMSO. In some
experiments, we also used Smo and Gli1targeting siRNAsMolecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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and performed fluorescence-activated cell sorting (FACS),
as indicated in the appropriate Figures or Figure legends.
Floating and adherent cells were harvested and resus-
pended in incubation buffer (100 μL/500 000 cells: 140
mmol/L NaCl, 5 mmol/L CaCl2, and 10 mmol/L HEPES
buffer) containing Annexin V-FITC and propidium iodide
(1 μg/mL) and incubated in a dark chamber at 4°C for 10
minutes. After centrifugation, the supernatant was with-
drawn and cells fixed in a dark chamber in 200 μL of for-
mol 1% at 4°C for 10 min. After centrifugation, cells were
resuspended in 200 μL incubation buffer and subjected to
FACS analysis. Fluorescence analysis were performed
using FACSort flow cytometer (BD) and the fraction of
viable cells, and apoptosis cells was determined using FCS
express software (DeNovo Software, Los Angeles, CA).
Xenograft Tumor Model
All animal studies were in compliance with the French
animal use regulations. Four million 786-0 cells were
injected s.c. under the skin of 4 week-old athymic male
mice (SWISS nu-/nu-; Charles River Laboratories,
l'Arbresle, France). Tumor volumes were measured as pre-
viously described [35]. We begun drug injections when
786-0 tumors had grown to an overall volume of 100
mm3. We followed two protocols: the first protocol was
injection of cyclopamine i.p at 0.5 mg/mouse at 2 days
interval for 19 days and the second protocol was injection
of cyclopamine i.p at 0.4 mg/mouse every day for 7 days,
the control groups receiving the vehicle alone (DMSO/oil,
v/v) at the same time period. Mice were thus divided in 4
groups, two groups treated with cyclopamine and 2
groups treated in control, according to the 2 protocols. For
the second protocol, the treatment was then followed for
4 days (day 7 to day 11) and mice were then left untreated
for additional 12 days (day 11 to day 23), and tumors
growth was measured. At the end of the treatments, ani-
mals were sacrified and the tumors were harvested, paraf-
fin embedded, and cut in 4-μm-thick sections for
subsequent immunohistochemical analysis as described
before for the proliferative index, the apoptotic index and
the neovascularization and snap-frozen for PCR or West-
ern blot analysis.
Statistical analysis
All values are expressed as mean ± s.e.m. Values were com-
pared using multifactorial analysis of variance followed
by the Student-Newman-Keul's test for multiple compari-
sons. A P < 0.05 was considered significant.
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Additional file 1
The silencing of the SHH signaling pathway decreases human CRCC 
cell proliferation. Tumor cells were seeded in 24-well plates (20,000 
cells/ml), grown for 24 h and were then transiently transfected for 24 to 
96 h with Smo-targeting siRNA (siSmo), Gli1-targeting siRNA (siGli1) 
or control siRNA (siCtl), according to the manufacturer's instructions 
(Applied Biosystems, Ambion local distributor, Courtaboeuf, France). (A) 
Human 786-0 cells were transiently transfected with siRNA (siCtl, siSmo 
and siGli1, as indicated) at 100 nM or not transfected (Ctl) and cells 
were counted each day. Results are shown as mean ± SEM, n = 6; *, P < 
0.05; **, P < 0.01 from Ctl. (B) Human 786-0 cells were transiently 
transfected for 4 days with siRNA (siCtl, siSmo, and siGli1, as indicated) 
or not transfected (Ctl) at the concentrations indicated in the figure and 
adherent cells were counted. Results are shown as mean ± SEM, n = 6; 
**, P < 0.01 from Ctl. (C) Our panel of human CRCC cells either defi-
cient or expressing the VHL gene were transiently transfected for 4 days 
with siRNA (siCtl, siSmo, and siGli1, as indicated) at 100 nM or not 
transfected (Ctl) and adherent cells were counted. Results are shown as 
mean ± SEM, n = 6; **, P < 0.01 from Ctl that was set to 100%. (D) 
Our panel of human CRCC cells either deficient or expressing VHL were 
analyzed for BrdU incorporation after transient transfection with siRNA 
(siCtl, siSmo, and siGli1, as indicated) at 100 nM or not transfected 
(Ctl) for the indicated periods of time. For clarity, only the results con-
cerning 786-0 cell line are presented since similar results were obtained 
with the other cell lines (dat not shown). Results are shown as mean ± 
SEM, n = 6; *, P < 0.05; **, P < 0.01 from corresponding Ctl.




The silencing of the SHH signaling pathway induces tumor cells apop-
tosis. FACS analysis of 786-0 cells transiently transfected with siRNA 
(siCtl, siSmo and siGli1, as indicated) at 100 nM or not transfected 
(Ctl). No evidence of necrosis was observed in any cases. The percent of 
apoptotic cells was quantified as a function of treatment times. Results are 
shown as mean ± SD, n = 6 *, P < 0.05 and **, P < 0.01 from Ctl apop-
tosis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-123-S2.TIFF]Molecular Cancer 2009, 8:123 http://www.molecular-cancer.com/content/8/1/123
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